| Name | TH1217 |
|---|---|
| Synonyms |
2-[4-[[5,6-Dichloro-2-methyl-4-nitro-1H-benzo[d]-imidazol-1-yl]methyl]phenyl]-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione
(T-4)-[N-[(Cboxy-κO)methyl]-N-methylglycinato(2-)-κN,κO][4-[(5,6-dichloro-2-methyl-4-nitro-1H-benzimidazol-1-yl)methyl]phenyl]boron Boron, [N-[(cboxy-κO)methyl]-N-methylglycinato(2-)-κN,κO][4-[(5,6-dichloro-2-methyl-4-nitro-1H-benzimidazol-1-yl)methyl]phenyl]-, (T-4) 3,TH |
| Description | TH1217 (ZINC1775962367) is a potent and selective dCTPase pyrophosphatase 1 (dCTPase) inhibitor, with an IC50 of 47 nM. TH1217 enhances the cytotoxic effect of cytidine analogues in leukemia cells. TH1217 also could modulate SARS-Cov-2 interactors, so it shows activity of against COVID-19[1][2]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 47 nM (dCTPase)[1] |
| In Vitro | TH1217 (compound 30) inhibits dCTPase and enhances aqueous solubility (>100 μM) and improves plasma stability in vitro(t4h=86%)[1]. TH1217 presents suitable mouse microsomal half-lives (109 minutes)[1]. TH1217 displays well cell permeability (8.66×10-6/1.30×10-3 cm/s) and CYP inhibition[1]. |
| References |
| Molecular Formula | C20H17BCl2N4O6 |
|---|---|
| Molecular Weight | 491.09 |
| Storage condition | -20°C |